Patents by Inventor Michael Joseph Coghlan

Michael Joseph Coghlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis
    Patent number: 8101761
    Abstract: The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Matthew William Carson, Michael Joseph Coghlan
  • Glucocorticoid receptor modulator and methods of use
    Patent number: 8101760
    Abstract: The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Matthew William Carson, Michael Joseph Coghlan
  • (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20100280062
    Abstract: The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 8, 2009
    Publication date: November 4, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Matthew William Carson, Michael Joseph Coghlan
  • GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE
    Publication number: 20100069425
    Abstract: The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 12, 2007
    Publication date: March 18, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Matthew William Carson, Michael Joseph Coghlan
  • TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
    Publication number: 20090149445
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Application
    Filed: July 15, 2008
    Publication date: June 11, 2009
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
  • Tricyclic steroid hormone nuclear receptor modulators
    Patent number: 7482344
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: January 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Michael Joseph Coghlan, Prabhakar Kondaji Jadhav, James Joseph Droste, Jonathan Edward Green, Donald Paul Matthews
  • Tricyclic steroid hormone nuclear receptor modulators
    Patent number: 7411072
    Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 12, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell